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Werdelin, 1986; Diment, 1990). Despite the absolute re-
quirement for Ii destruction to render class II molecules
capable of binding peptide, the primary proteases that
perform this task remain unidentified. Previous attemptsSummary
at identifying these proteases are difficult to interpret,
owing to the rather nonspecific action of the inhibitorsDestruction of Ii by proteolysis is required for MHC
used and possible contamination of commercially avail-class II molecules to bind antigenic peptides, and for
able protease preparations with other proteases. Fortransport of the resulting complexes to the cell sur-
example, leupeptin, a commonly utilized protease inhibi-face. The cysteine protease cathepsin S is highly
tor (Nguyen et al., 1988), acts on many proteases of theexpressed in spleen, lymphocytes, monocytes, and
cysteine and serine class. Lysosomotropic agents, suchother class II±positive cells, and is inducible with
as quinidine (Humbert et al., 1993) and concanamycininterferon-g. Specific inhibition of cathepsin S in B
B (BeÂ naroch et al., 1995), neutralize acidic compart-lymphoblastoid cells prevented complete proteolysis
ments in a nonspecific manner. Also, analysis of someof Ii, resulting in accumulation of a class II±associated
commercially available cathepsin B preparations in our13 kDa Ii fragment in vivo. Consequently, the formation
laboratory have demonstrated the presence of addi-of SDS-stable complexes was markedly reduced. Puri-
tional cysteine proteases (H. A. C., unpublished data).fied cathepsin S, but not cathepsin B, H, or D, specifi-
Cathepsin S, a cysteine protease originally clonedcally digested Ii from abIi trimers, generating ab±CLIP
from human alveolar macrophages, is highly expressedcomplexes capable of binding exogenously added
in the spleen and professional antigen-presenting cells,
peptide in vitro. Thus, cathepsin S is essential in B including B lymphocytes, macrophages, and other class
cells for effective Ii proteolysis necessary to render II±positive cells (Shi et al., 1992, 1994; Morton et al.,
class II molecules competent for binding peptides. 1995). Moreover, it is inducible with interferon-g (IFNg),
it is a potentendoprotease, and ithas a broad pH activity
profile (Shi et al., 1992, 1994; H. A. C., unpublished data;Introduction
BroÈ mme et al., 1993). These characteristics distinguish
cathepsin S from other cysteine proteases, and make
Major histocompatibility complex (MHC) class II ab het-
cathepsin S an ideal candidate for Ii processing. To
erodimers associate early during biosynthesis with a
avoid the problems associated with the use of less spe-
type II membrane protein, the invariant chain (Ii) (Roche cific inhibitors or impure protease preparations, we uti-
et al., 1991; Lamb and Cresswell, 1992). The Ii contains lized a novel specific irreversible inhibitor of cathepsin
a signal in its cytoplasmic tail (Lotteau et al., 1990; Bakke S, and purified recombinant enzyme (BroÈ mme and
and Dobberstein, 1990) that delivers a nonameric com- McGrath, 1996), to probe directly the relationship be-
plex of abIi to intracellular compartments with late endo- tween cathepsin S activity, Ii proteolysis, and subse-
somal/lysosomal characteristics (Amigorena et al., quent peptide binding by class II molecules. Cathepsin
1994; Tulp et al., 1994; West et al., 1994). In these acidic S alone, in marked contrast with other endosomal prote-
compartments, class II molecules encounter and bind ases, was required for efficient Ii processing to permit
antigenic peptides, and are then deposited on the cell subsequent peptide binding by class II molecules. These
surface for recognition by CD41 T helper cells. Ii associ- findings suggest that cathepsin S, along with HLA-DM,
ates with class II molecules via direct interaction of resi- may be new essential elements for MHC class II antigen
dues 81±104 of its lumenal domain (Bijlmakers et al., presentation.
1994; Ghosh et al., 1995), designated class II±associated
invariant chain peptides (CLIP), with the antigen-binding Results
groove of class II (Rudensky et al., 1991; Riberdy et al.,
1992; Chicz et al., 1992). Most class II alleles require an Active Site Labeling of Cysteine Proteases
additional class II±like molecule, HLA-DM, to liberate The role of cathepsin S in the proteolytic processing
of Ii was investigated by exploiting the properties of athe peptide-binding groove of CLIP, and to facilitate
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Figure 1. Cbz±[125I]±Tyr±Ala±CN2 Labeling of HOM2 Cells and Purified Human Cathepsins
(A) HOM2 cells were labeled with active site cysteine protease inhibitor Cbz±[125I]±Tyr±Ala±CN2 after incubation with 0, 1, and 5 nM specific
cathepsin S inhibitor LHVS, lysed and analyzed by 12% SDS±PAGE.
(B) HOM2 cells were labeled as above without inhibitor, lysed and immunoprecipitated with an antibody against cathepsin S and an antibody
against cathepsin B, and analyzed by 12% SDS±PAGE.
(C) Purified human cathepsins B and S were labeled as above and analyzed by 14% SDS±PAGE.
number of protease inhibitors, both novel and previously and 6 kDa polypeptides were immunoprecipitated with
an antiserum specific for cathepsin B (Figure 1B), anddescribed. The cysteine protease inhibitor Cbz±Tyr±Ala±
CN2 irreversibly binds to the active site of cysteine prote- represent the single and light chain forms of the active
enzyme, respectively. The more intense labeling of theases in proportion to their activity. A profile of the active
cysteine proteases present within a given cell type can 6 kDa polypeptide compared with the 33 kDa protein
suggests that most of the cathepsin B present in HOM2be directly established by incubating the cells with an
iodinated form of this inhibitor, Cbz±[125I]±Tyr±Ala±CN2, cells is in the light chain form. The 28 kDa polypeptide
was identified as the active form of cathepsin S, as itand visualizing the labeled proteases on SDS±PAGE
(Mason et al., 1989). Cysteine proteases in the cell that was immunoprecipitated with an antibody specific for
this enzyme (Figure 1B). The labeling of cathepsin S,are first inactivated with other cysteine class inhibitors
prior to incubation with Cbz±[125I]±Tyr±Ala±CN2 produce but not cathepsin B, was effectively inhibited at an LHVS
concentration of 1 nM (Figure 1A). At an inhibitor con-a corresponding decrease in labeling. Inhibition specific
for a given protease will affect subsequent labeling with centration of 5 nM, the labeling of cathepsin B was
decreased, although some activity remained. Thus,Cbz±[125I]±Tyr±Ala±CN2 of that particular protease, but
not other enzymes present in the preparation. To exam- LHVS can be utilized at 1±5 nM concentrations to inhibit
specifically cathepsin S in HOM2 cells, leaving otherine the cysteine protease profile of professional antigen-
presenting cells, and measure specifically the activity cysteine proteases functionally active. The active site
labeling of cysteine proteases with Cbz±[125I]±Tyr±Ala±of cathepsin S, the B lymphoblastoid cell line HOM2
was labeled with Cbz±[125I]±Tyr±Ala±CN2 after incubation CN2 was then used to determine that the purified human
cathepsins B and S, used in subsequent experimentswith varying concentrations of the specific cathepsin S
inhibitor, morpholinurea±leucine±homophenylalanine± described in this manuscript, were not cross-contami-
nated with other proteases (Figure 1C).vinylsulfone±phenyl (LHVS). LHVS has a second order
rate constant for inhibition of cathepsin S, which is 67
times greater than that for cathepsin L and 6000 times
greater than that for cathepsin B, illustrating the high Inhibition of Cathepsin S Prevents Ii Processing
To determine whether inhibition of cathepsin S interferesdegree of specificity for inhibition of cathepsin S activity
(Palmer et al., 1995). Lysates prepared from the labeled with processing of Ii and subsequent peptide binding
by class II molecules, HOM2 cells were pulsed-labeledcells were analyzed either directly (Figure 1A), or sub-
jected to immunoprecipitation with antibodies specific with [35S]methionine/cysteine and chased for 5 hr in the
presence or absence of LHVS, followed by immunopre-for cathepsins S and B (Figure 1B). In the absence of
cathepsin S inhibitor, three polypeptides were labeled, cipitation of class II ab dimers and abIi complexes with
the monoclonal antibody (MAb) TuÈ 36 (Figure 2). One halfmigrating at 33 kDa, 28 kDa, and 6 kDa (running with
the dye front in this 12% gel) (Figure 1A). The 33 kDa of the samples were analyzed under mildly denaturing
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(Figure 2A, lane 4), similar to that seen with leupeptin.
This suggests that cathepsin S acts on a relatively late
Ii breakdown intermediate and is required for efficient
proteolysis of Ii necessary for subsequent peptide
loading.
Cathepsin S Selectively Digests Ii
Participating in abIi Complexes
To examine the effects of proteolysis by cathepsin S on
class II molecules and Ii, individual a, b, and Ii polypep-
tides were translated in vitro both separately and to-
gether under conditions compatible with complex for-
mation (Bijlmakers et al., 1994), followed by digestion
with varying concentrations of purified cathepsin S at
pH 5.5. Cathepsin S readily digested the a, b, and Ii
chains when translated alone (Figure 3). However, when
the a and b chains were translated together so that
dimer formation occurred, they displayed resistance to
proteolysis. When all three moieties were translated to-
gether and digested with cathepsin S, only Ii was de-Figure 2. Inhibition of Cathepsin S and Its Effect on Ii Processing
and Formation of SDS-Stable Complexes In Vivo graded, illustrating the marked sensitivity of Ii to cathep-
sin S digestion (Figure 3). The formation of ab dimersHOM2 cells were labeled with [35S]methionine/cysteine and chased
for 5 hr without inhibitor (lanes 1, 5), in the presence of 1 nM LHVS and abIi trimers were confirmed following each step by
(lanes 2, 6), 5 nM LHVS (lanes 3, 7), and 20 mM E64D (lanes 4, 8). immunoprecipitation (data not shown). Thus, cathepsin
Class II±Ii complexes were immunoprecipitated from cell lysates S selectively degrades Ii molecules that are part of abIi
with MAb TuÈ 36 and analyzed by 14% SDS±PAGE under mildly dena-
complexes, leaving the ab dimers intact.turing conditions (nonboiled, nonreduced) (lanes 1±4) and denatur-
Can cathepsin B digest abIi complexes with similaring conditions (lanes 5±8).
efficiency? To compare directly the ability of cathepsins
S and B to degrade Ii participating in abIi trimers, the
activity of the two proteases must be measured, inde-(nonboiled, nonreduced) conditions (Figure 2A) to visu-
alize SDS-stable complexes that migrate at approxi- pendent of their differences in substrate specificity. Nor-
malization to total protein content is misleading becausemately 50 kDa. These SDS-stable complexes represent
peptide-loaded ab dimers, which decrease upon inhibi- only a portion of the total protein may be active. To
overcome this difficulty, the molar activity of the purifiedtion of cysteine proteases with leupeptin (Neefjes and
Ploegh, 1992). Specific inhibition of cathepsin S with 1 cathepsin B and cathepsin S preparations were mea-
sured by using E64D as an active site titrant with thenM and 5 nM LHVS resulted in accumulation of a class
II±associated 13 kDa Ii fragment, and a concomitant substrate Z±Phe±Arg±AMC, as previously described
(Barrett and Kirschke, 1981). The activities of the en-reduction in peptide loading as evidenced by a marked
decrease in formation of SDS-stable complexes (Figure zymes measured in this manner are independent of the
substrate used, because E64D irreversibly inhibits both2A, lanes 2, 3). Inhibition of all cysteine proteases with
the cysteine-class inhibitor 2S, 3S-trans-epoxysuccinyl- cathepsins S and B on an equimolar basis.
Using the concentrations determined by the aboveL-leucylamido-3-methylbutane ethyl ester (E64D) re-
sulted in a buildup of a class II±associated 23 kDa Ii method, the ability of cathepsins S and B to digest Ii
from abIi heterotrimers immunoprecipitated from HOM2fragment with a decrease in SDS-stable dimer formation
Figure 3. Digestion of In Vitro-Translated a,
b, Ii Polypeptides with Purified Human Ca-
thepsin S
MHC class II a chains, b chains, and Ii were
translated alone (lanes 1±9), or together (a 1
b chains, lanes 10±12; a 1 b 1 Ii, lanes 13±15)
followed by digestion with cathepsin S at pH
5.5. Translations were performed in condi-
tions known to form ab dimers and abIi com-
plexes as previously reported (Bijlmakers et
al., 1994). Cathepsin S concentrations were
0 mM (lanes 1, 4, 7, 10, 13), 0.19 mM (lanes 2,
5, 8, 11, 14), and 0.38 mM (lanes 3, 6, 9, 12, 15).
Samples were analyzed by 15% SDS±PAGE
under denaturing conditions.
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Figure 4. Digestion of Immunoprecipitated
abIi Trimers with Purified Human Cathepsins
S and B
(A) HOM2 cells were labeled with [35S]methio-
nine/cysteine and chased for 5 hr in the ab-
sence and presence of inhibitors, lysed, and
immunoprecipitated with TuÈ 36. Immunopre-
cipitates were then digested with purified ca-
thepsin S at 0 mM (lanes 1, 4, 7), 0.23 mM
(lanes 2, 5, 8), and 0.76 mM (lanes 3, 6, 9), and
analyzed by 14% SDS±PAGE under mildly de-
naturing conditions (nonboiled, nonreduced).
(B) HOM2 cells were labeled and immunopre-
cipitated as in (A), and then were subjected
to digestion with purified human cathepsin B
at 0 mM (lanes 1, 4, 7), 6.6 mM (lanes 2, 5,
8), and 22 mM (lanes 3, 6, 9). Conditions for
SDS±PAGE analysis were identical to those
above.
cells was determined. HOM2 cells were incubated in A defined intermediate in the maturation of class II
molecules is a complex consisting of the ab heterodimerthe absence of inhibitor (Figure 4, lanes 1±3), or in the
presence of inhibitors E64D (lanes 4±6) or LHVS (lanes bound to the CLIP region of Ii (Avva and Cresswell,
1994). It is this intermediate that was proposed to be a7±9), during a [35S]methionine/cysteine pulse-chase. Ca-
thepsin S specifically degraded intact Ii as well as the substrate for HLA-DM. To determine whether cathepsin
S could generate ab±CLIP from abIi, HOM2 cells were23 kDa and 13 kDa Ii intermediates, while sparing the
ab dimer and the ab±peptide complexes (Figure 4A). In labeled in theabsence and presence of inhibitors, immu-
noprecipitated with the MAb TuÈ36, digested with ca-contrast, cathepsin B showed little proteolytic activity
against immunoprecipitated abIi trimers or abIi frag- thepsin S, and reimmunoprecipitated with antibodies
directed against Ii (Figure 5A). Following digestion withment complexes, even at 1003 the molar concentration
of cathepsin S. The inability of cathepsin B to digest Ii cathepsin S, a 3 kDa polypeptide was immunoprecipi-
tated with an anti-CLIP antibody (Figure 5A, lanes 4, 6),was not merely a result of the enzyme not being active
at the concentrations used, as evidenced by the slight which was not found in the undigested samples (lanes
3, 5). An antibody directed against the N-terminal cyto-change in migration of the class II b chain (Figure 4B,
compare lane 3 with lane 4), suggesting activity of ca- plasmic tail, PIN-1, was able to immunoprecipitate intact
Ii as well as the 23 kDa and 13 kDa Ii chain fragmentsthepsin B on the cytoplasmic portion of the b chain
(Roche and Cresswell, 1991). (Figure 5A, lanes 1, 3, and 5), suggesting that both the 23
Essential Role of Cathepsin S in Ii Processing
361
Figure 5. Generation of ab±CLIP Complexes from Immunoprecipi-
tated abIi Trimers by Digestion with Cathepsin S
(A) HOM2 cells were labeled with [35S]methionine/cysteine and
chased for 5 hr in the absence and presence of inhibitors, immuno-
precipitated with TuÈ 36 MAb, and digested with 0.23 mM cathepsin
S for 1 hr at 378C. Immunoprecipitates were then boiled for 3 min
in the presence of 1% SDS to unfold the abIi complexes, diluted 10-
fold, and reimmunoprecipitated sequentially with antibodies against
the CLIP region (left), cytoplasmic tail (PIN-1 antibody, center), and
lumenal domain (LN-2 antibody, right) of Ii. Samples were analyzed
by 10%±20% gradient tricine SDS±PAGE under denaturing condi-
tions.
(B) HOM2 cells were labeled with [35S]methionine/cysteine and
chased for 5 hr in the presence of 0.5 mM leupeptin, immunoprecipi-
tated with TuÈ 36, and incubated at pH 5.5 in the absence of enzyme
(lane 1), 0.23 mM cathepsin S (lane 2), 66 mM cathepsin B (lane 3),
and 2.4 mM cathepsin D (lane 4) for 1 hr at 378C. The digested
complexes were then analyzed by 10%±20% tricine gel under dena-
turing conditions.
Abbreviations: minus, no inhibitor; E, 20 mM E64D; L, 5 nM LHVS;
S, cathepsin S; B, cathepsin B; D, cathepsin D.
kDa and 13 kDa intermediates are N-terminal fragments. not shown). Both cathepsins B and D, when used at high
concentrations, could produce large molecular weightThe LN-2 antibody against the Ii lumenal domain precipi-
tated only the full-length Ii (Figure 5A, lanes 1, 3, and Ii cleavage products, but not ab±CLIP, illustrating the
essential role of cathepsin S in complete and efficient5). Thus, cathepsin S is able to produce ab±CLIP, a
known intermediate in abIi proteolysis. Ii processing.
While inclusion of HLA-DM facilitates exchange ofIn contrast with cathepsin S, neitherpurified cathepsin
B nor D could produce ab±CLIP from abIi (Figure 5B). CLIP bound to the ab±CLIP complex for antigenic pep-
tide (Denzin and Cresswell, 1995; Sherman et al., 1995;HOM2 cells were pulse±chased in the presence of leu-
peptin and class II molecules were immunoprecipitated Sloan et al., 1995), the reaction can also occur, albeit
less efficiently, in the absence of added HLA-DM. Thewith TuÈ 36. The isolated class II complexes were then
digested with the different purified cathepsins. Diges- displacement of larger Ii remnants with antigenic pep-
tides is even less efficient. Can proteolysis of abIi heter-tion with cathepsin S alone resulted in the production
of a 3 kDapolypeptide associated with ab dimers (Figure otrimers with cathepsin S allow peptide loading onto
the resulting class II ab±CLIP complexes? HOM2 cells5B, lane 2). This 3 kDa fragment could also be reimmuno-
precipitated with the anti-CLIP reagent used above (data were treated with concanamycin B toaccumulate a large
Immunity
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Figure 6. Digestion of abIi Complexes with
Cathepsin S Generates Class II Molecules
Capable of Binding Peptide
HOM2 cells were labeled with [35S]methio-
nine/cysteine and chased for 5 hr in the pres-
ence of 20 nM concanamycin B. Class II±Ii
complexes were immunoprecipitated from
cell lysates with LN-2. These immunoprecipi-
tates were then incubated at pH 5.5 in the
absence (lane 1) and presence (lane 2) of 0.23
mM human cathepsin S and immediately
placed in SDS±PAGE sample buffer to stop
the digestion. In a parallel experiment, unla-
beled concanamycin B±treated HOM2 cells
were lysed and the class II±Ii complexeswere
immunoprecipitated with LN-2. These immu-
noprecipitates were incubated in the absence
(lane 3) and presence (lane 4) of 0.23 mM ca-
thepsin S. The digested precipitates were
then exposed to 125I±HA at pH 5.5 for 4 hr.
Samples were diluted to 0.8 ml with lysis
buffer, precleared of LN-2 antibody, and im-
munoprecipitated with TuÈ 36. All samples
were analyzed by 14% SDS±PAGE under
mildly denaturing (nonboiled, nonreduced)
conditions.
amount of abIi trimers (BeÂ naroch et al., 1995). The hem- shown), implying that cathepsin H is not an essential
protease for Ii degradation.agglutinin peptide (HA), containing amino acids 306±
318, was used as a DR1-restricted peptide (Rothbard
et al., 1988). The abIi complexes from concanamycin Discussion
B±treated cells were initially immunoprecipitated with
an antibody against the Ii lumenal domain (LN-2) to pre- A noteworthy feature of the various components of the
cipitate only intact abIi complexes (Figure 6). These class II±restricted antigen presentation pathway is that
complexes were incubated in the absence and presence
of cathepsin S at pH 5.5, and then exposed to 125I±HA
at the same acidic pH. After removal of unbound 125I±HA,
complex formation was assessed by SDS±PAGE. Diges-
tion of abIi with cathepsin S and subsequent exposure
to 125I±HAresulted in the formation of labeled ab±peptide
complexes, although this conversion was incomplete
as evidenced by the continued presence of SDS-labile
class II molecules (data not shown). Cathepsin S is thus
able to process Ii while leaving the class II molecules
functionally intact, which shows that cathepsin S issuffi-
cient, by itself, to effectively degrade Ii in a manner that
renders ab dimers capable of binding peptide.
Inhibition of Cathepsin D Does Not
Effect Ii Processin
Maric et al. (1993) have implicated the aspartyl protease
cathepsin D in an early step of Ii breakdown. To examine
this question in our system, a potent aspartyl class pro-
tease inhibitor, CGP 53437, which inhibits cathepsin D
in the nanomolar range, was utilized. CGP 53437 inhibits
cathepsin D activity in human monocytes by 75% and
90% at concentrations of 5 mM and 50 mM, respectively
(D. Simon et al., unpublished data). Inhibition of cathep-
sin D with CGP 53437 did not result in accumulation of
Ii fragments nor did it produce a decrease in SDS-stable
complexes (Figure 7), suggesting that cathepsin D is
Figure 7. Inhibition of Aspartyl Proteases Does Not Effect Ii Pro-
not essential for Ii processing. cessing
Cathepsin H, a lysosomal cysteine protease with good
HOM2 cells were labeled with [35S]methionine/cysteine and chased
aminopeptidase but weak endopeptidase activity, is up- for 5 hr without inhibitor (lane 1), in the presence of 0.5 mM leupeptin
regulated by IFNg in mouse peritoneal macrophages (lane 2), 5 nM LHVS (lane 3), 5 mM CGP 53437 (lane 4), and 50 mM
(Lafuse et al., 1995). Purified human cathepsin H was CGP 53437 (lane 5). Samples were analyzed by 14% SDS±PAGE
not inhibited by LHVS nor did it display any proteolytic under mildly denaturing conditions. Abbreviations: minus, no inhibi-
tor; Leu, 0.5 mM leupeptin; L, 5 nM LHVS; CGP, CGP 53437.activity against immunoprecipitated abIi (data not
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they appear to be regulated in a coordinate fashion. that these additional proteases may provide a less effi-
cient salvage pathway for Ii processing, used only whenExpression of the structural genes that encode class II
a and b chains, Ii, and the accessory molecule HLA- cathepsin S is absent.
Because cathepsin S is able to generate ab±CLIPDM, are all under the control of the MHC class II trans-
activator, CIITA (Steimle et al., 1993, 1994; Siegrist et complexes from intact abIi, it may thus be responsible
for creating a suitable substrate for HLA-DM. In vitroal., 1995). In professional antigen-presenting cells, CIITA
regulates both constitutive as well as IFNg-induced ex- experiments with both immunoprecipitated (Denzin and
Cresswell, 1995; Sherman et al., 1995) and soluble DMpression of these essential components of the class II
processing and presentation pathway (Steimle et al., (Sloan et al., 1995) have clearly shown that HLA-DM
induces removal of CLIP from ab±CLIP complexes, per-1993, 1994). However, it would be naive to assume that
all of the components involved in loading class II mole- mitting, as well as facilitating, peptide loading. Inhibition
of the N-terminal cleavage performed by cathepsin Scules with peptide are subject to control by a single
transcription factor, and that all of the essential players may therefore inhibit DM-mediated dissociation of Ii-
breakdown intermediates (i.e., CLIP). Just as the affinityhave been identified. Indeed, induced expression of the
class II subunits, Ii and HLA-DM in melanoma cells via of class II molecules for CLIP and the requirement for
HLA-DM to remove CLIP appears to vary between classtransfection of CIITA alone, was not sufficient to achieve
effective processing and presentation of protein antigen II alleles (reviewed by Wolf and Ploegh, 1995; Sette et
al., 1995), allelic variation may dictate dependency on(Siegrist et al., 1995). In contrast, IFNg stimulation by
itself did confer the ability to present antigen in a class the proteolytic activity of cathepsin S to effectively re-
move Ii. In other class II±positive cells, we cannot ruleII±restricted fashion, and corrected the antigen-presen-
tation defect of the CIITA transfectants. Thus, additional out the participation of lysosomal enzymes with a sub-
strate profile similar to that of cathepsin S (i.e., cathepsinIFNg-inducible factor(s), necessary to load class II mole-
cules with antigenic peptide effectively, must exist (Sie- L), absent from the B lymphoblastoid cell line utilized in
the present study.grist et al., 1995).
We now provide evidence that the cysteine protease, Although cathepsin S may be the primary protease
involved in Iibreakdown, it is certainly not the only prote-cathepsin S, is one of these, as yet unrecognized, essen-
tial elements. A priori, cathepsin S is an excellent candi- ase essential to class II±restricted antigen presentation.
Proteases are not only necessary for Ii breakdown, butdate for participation in the breakdown of Ii because it
is a potentendopeptidase, has a broad pH activity range are required in the processing of protein antigen for
presentation by class II molecules. Thus, other lyso-(Shi et al., 1994; BroÈ mme et al., 1993), and is present in
class II±positive antigen-presenting cells, including B somal enzymes, i.e., cathepsins B, H, D, and E, may
primarily function in generating epitopes for capture bylymphocytes (Morton et al., 1995), macrophages (Shi et
al., 1994), and bone marrow±derived mouse dendritic ab dimers made competent tobind peptide by exposure
to cathepsin S (Matsunaga et al., 1993; Rodriguez andcells (E. Schneeburger and R. J. R., unpublished data).
We here show that cathepsin S, unlike cathepsins B or Diment, 1992; Bennett et al., 1992). It is notable that
cathepsins H and B arepotent amino- and carboxypepti-D, is required for complete Ii proteolysis, a step that
is necessary for subsequent peptide loading in the B dases, respectively. The action of cathepsin D has been
revealed in the generation of peptides suitable for bind-lymphoblastoid cell line HOM2. In addition, inhibition of
cathepsin S attenuated tetanus toxoid±stimulated T cell ing to class II molecules (Van Noort and van der Drift,
1989; Van Noort et al., 1991).proliferation fromimmune individuals inperipheral blood
mononuclear cells, implicating participation of cathep- What, then, is the specific substrate for the proteolytic
activity of cathepsin S? The 13 kDa Ii fragment thatsin S in presentation of peptide antigen by class II mole-
cules (data not shown). accumulates when cathepsin S activity is inhibited can
be coprecipitated with class II molecules by an antibodySpecific inhibition of cathepsin S activity in HOM2
cells resulted in an accumulation of class II molecules against the cytoplasmic tail of Ii, but not with an antibody
directed against the lumenal domain. In a similar fashion,associated with a 13 kDa Ii fragment, and a concomitant
reduction in the appearance of SDS-stable complexes. cells exposed to the cysteine protease inhibitor leupep-
tin accumulate a number of Ii breakdown products thatThus, in the absence of cathepsin S, class II±associated
Ii molecules are susceptible to attack by other prote- remain associated with class II ab chains (Neefjes and
Ploegh, 1992), thus preventing peptide loading and in-ases, but the action of these proteases may not allow
the production of the intermediates that favor peptide tracellular transport of these molecules. One such
N-terminal fragment, designated small leupeptin-in-binding to class II molecules. Whether the activity we
invoke for such additional proteases is essential in the duced peptide (SLIP) (Nguyen et al., 1988), is similar in
molecular mass to the 13 kDa Ii fragment that accumu-course of normal breakdown of Ii is not clear. A 23
kDa Ii processing intermediate may be generated by lated when cathepsin S activity was inhibited. A similar
N-terminal SLIP-like fragment is found associated withnoncysteine proteases, which is then further digested
by cysteine proteases other than cathepsin S to gener- class II when the macrolide antibiotic concanamycin
B is used to inactivate cellular vacuolar H1 ATPases,ate the 13 kDa intermediate. This 13 kDa intermediate
could serve as the final substrate for complete proteoly- neutralizing the endocytic compartmentswhere Ii break-
down and peptide binding occur (BeÂ naroch et al., 1995).sis by cathepsin S. However, given that in vitro, cathep-
sin S alone was capable of generating ab±CLIP com- Thus, the accumulation of class II molecules associated
with SLIP-like fragments when the above inhibitors areplexes capable of binding peptide, it appears more likely
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[35S]methionine/cysteine and 125I were obtained from DuPont Newused may be a direct consequence of cathepsin S inhibi-
England Nuclear (Boston, Massachusetts). Protein A±agarose wastion. The smallest N-terminal Ii fragment that can associ-
purchased from Boerhinger Mannheim (Indianapolis, Indiana). Me-ate with ab dimers and effectively inhibit peptide binding
thionine-free cysteine-free Dulbecco's modified Eagle's medium
is comprised of amino acids 1±104 (Bijlmakers et al., (DMEM), penicillin/streptomycin (1003), HEPES (1003), and gluta-
1994), which includes the CLIP region. Whereas other mine (1003) were obtained from GIBCO BRL (Gaithersburg, Mary-
land). RPMI was purchased from Fisher (Pittsburgh, Pennsylvania)proteases may be able to digest the C terminus of Ii,
and fetal bovine serum (FBS) was obtained from Hyclone (Logan,cathepsin S appears essential for cleavage of the N
Utah). Normal rabbit serum, normal mouse serum, and Histopaqueterminus, a necessary step in generating ab±CLIP com-
were purchased from Sigma. Iodogen was obtained from Pierceplexes. Because the N-terminal cytoplasmic tail of Ii
(Rockford, Illinois) and the C18 Sep-pak column was purchased
contains thesignals for sorting and retention (Amigorena from Waters, Incorporated (Milford, Massachusetts).
et al., 1994), removal of this segment by cathepsin S
would also be necessary to free class II molecules from Antibodies
TuÈ 36 is a mouse MAb (Shaw et al., 1985) that recognizes HLA-DR1the retention mechanisms imposed by Ii and to allow
ab dimers alone or in association with Ii. Two Ii-reactive mousetransport to the cell surface.
MAbs were used: PIN-1, specific for the N terminus of Ii, providedFinally, based on the preferred substrate specificities
by Dr. P. Cresswell (Yale University, New Haven, Connecticut), and
of cathepsin S, we can hypothesize as to its likely cleav- the MAb LN-2, directed against the C terminus of Ii, provided by
age sites near the N terminus of the CLIP region. Both Dr. A. Epstein (University of Southern California Medical School,
Arg and Lys are good P1 residues for proteolysis by Los Angeles, California). The anti-CLIP reagent was generated by
the laboratory of Dr. E. Weirtz (National Institute of Public Healthcysteine proteases (Mason et al., 1984, 1985), and ca-
and Environmental Protection, Netherlands) by injection of rabbitsthepsin S prefers branched nonpolar residues such as
with two overlapping peptides, conjugated to KLH, spanning theLeu or Val in the P2 position (BroÈ mme et al., 1989). This
region of residues 81±104 of intact human Ii. Antibody to human
suggests that the Arg±Met bond between amino acids cathepsin S was prepared as described previously (Shi et al., 1994),
78 and 79 with Leu in the P2 position, or the Lys±Leu and antibody to cathepsin B was purchased from Vital Products,
bond between amino acids 80 and 81 with Met in the Incorporated (St. Louis, Missouri).
P2 position, may be good substrates for cathepsin S.
Cell CultureCLIP fragments have been eluted from class II molecules
The B lymphoblastoid cell line HOM2 (homozygous for HLA-DR1)exhibiting N termini beginning at amino acids 81±83,
was maintained in RPMI with 10% FBS, 1/1000 U/ml penicillin, 100
consistent with the putative cathepsin S cleavage sites
mg/ml streptomycin, and 2 mM glutamine.
listed above (Riberdy et al., 1992; Chicz et al., 1992).
Further modification of the N terminus in vivo may occur Active Site Labeling of Cysteine Proteases
following cathepsin S cleavage by endogenous amino- The cysteine protease inhibitor Cbz±Tyr±Ala±CN2 was iodinated as
previously reported (Mason et al., 1989). HOM2 cells (5 3 106 cells/peptidases.
sample) were incubated with inhibitors E64D (20 mM), leupeptin (0.5In summary, the finding that a single protease is cru-
mM), concanamycin B (20 nM), or LHVS (1 or 5 nM) at 378C for 1 hrcial for Ii proteolysis issurprising indeed, and hasseveral
prior to labeling. Cells were labeled by incubation with Cbz±[125I]±
important implications both in the fields of lysosomal Tyr±Ala±CN2 for 1 hr at 378C, washed twice with phosphate-buffered
biology and immunology. This finding contrasts the prior saline, and lysed in the SDS±PAGE sample buffer. The purified ca-
view of lysosomes as pools of enzymes that mediate thepsins B and S were labeled by addition of a 2 ml aliquot of purified
enzyme stock to 50 ml of digestion buffer (50 mM Na acetate [pHterminal degradation of endocytosed protein (Barrett
5.5], 1% Triton X-100, 3 mM cysteine, 1 mM EDTA) containing Cbz±and Kirschke, 1981). Cathepsin S expands the list of
[125I]±Tyr±Ala±CN2. Samples were incubated for 1 hr at 378C andcomponents essential to class II antigen presentation,
the labeling reaction was stopped by the addition of 50 ml of 23
and implies that the enzymes that mediate Ii proteolysis SDS±PAGE sample buffer.
and antigen processing may be distinct. In turn, this Immunoprecipitation of cathepsins B and S was performed by
makes targeting of cathepsin S a possibility for modulat- labeling 5 3 106 HOM2 cells as above followed by cell lysis with 1
ml of 10 mM Tris±HCL (pH 7.5), 1 mM EDTA, 0.2% SDS, 1% Tritoning class II±restricted immune responses.
X-100 on ice. Lysates were collected, boiled for 5 min, and pre-
cleared with protein A±agarose (Boerhinger Mannheim, Indianapo-
lis, Indiana) plus normal rabbit serum (Sigma). The cysteine prote-Experimental Procedures
ases were immunoprecipitated with anti-cathepsin S antibody and
anti-cathepsin B antibody coupled to protein A±agarose. The pelletsMaterials
were washed and eluted with reducing SDS±PAGE sample buffer.Cbz±Tyr±Ala±CN2 was a gift from Dr. E. Shaw (Friedrich Miescher-
Institut, Basel, Switzerland). E64D and leupeptin were obtained from
Sigma Chemical Company (St. Louis, Missouri). LHVS, an irrevers- Metabolic Labeling, Class II Immunoprecipitation,
and Proteolytic Digestionible specific cathepsin S inhibitor, was provided by Dr. J. T. Palmer
(Arris Pharmaceuticals, South San Francisco, California) (Palmer et HOM2 cells, 5 3 106/sample, were preincubated in 1 ml methionine-
free cysteine-free DMEM supplemented with protease inhibitors oral., 1995). CGP 53437 was provided by Ciba±Geigy, Limited (Basel,
Switzerland) (Alteri et al., 1993). Stock solutions of these inhibitors appropriate solvent for 1 hr at 378C prior to labeling with 0.25 mCi
[35S]methionine/cysteine for 1 hr at 378C. The cells were centrifugedwere made in dimethyl sulfoxide. Concanamycin B was obtained
from Ajinomoto Corporation (Kanagawa, Japan). A 10 mM stock and resuspended at 1 3 106/ml in RPMI, 10% FBS and chased for
5 hr in the presence of protease inhibitors or solvent. The HOM2solution was prepared in ethanol. Purified human cathepsin S was
obtained by expression in Sf9 cells using theBaculovirus expression cells were then washed twice with cold phosphate-buffered saline
and lysed in 1 ml of 50 mM Tris±HCL (pH 7.4), 0.5% NP-40, 5 mMsystem as described (BroÈ mme and McGrath, 1996). Purified human
cathepsins B, D, and H were obtained from Calbiochem± MgCl2. Lysates were precleared with protein A±agarose, 7 ml of
normal rabbit serum, and 2 ml of normal mouse serum followed byNovabiochem Corporation (San Diego, California). HA, a DR1-pre-
sentable peptide (amino acids 306±318), was synthesized (t-boc immunoprecipitation with antisera coupled to protein A±agarose.
Immunoprecipitates were washed 4±6 times with 1 ml of 50 mMchemistry) on a Biosearch SAM 2 peptide synthesizer, dissolved in
H2O, and stored at 2708C. Tris±HCL (pH 7.4), 0.5% NP-40, 5 mM EDTA, 150 mM NaCl. These
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pellets were either eluted directly with nonreducing or reducing and dissociation of HLA-DR complexes with invariant chain±derived
peptides. Immunity 1, 763±774.SDS±PAGE sample buffer, orused as starting material for proteolytic
digestion and further immunoprecipitation. Bakke, O., and Dobberstein, B. (1990). MHC class II±associated
Proteolytic digestion of immunoprecipitates was performed by invariant chain contains a sorting signal for endosomal compart-
incubation of precipitated pellets with purified proteases diluted in ments. Cell 63, 707±716.
50 ml of 50 mM Na acetate (pH 5.5), 1% Triton X-100, 3 mM cysteine,
Barrett, A. J., and Kirschke, H. (1981). Cathepsin B, Cathepsin H,
1 mM EDTA at 378C. Samples were eluted with SDS±PAGE sample
Cathepsin L. Meth. Enzymol. 80, 535±560.
buffer.
Bell, J.I., Estess, P., John, T.S., Saiki, R., Watling, D.L., Erlich, H.A.,
and McDevitt, H.O. (1985). DNA sequence and characterization of
Peptide Loading
human class II major histocompatibility complex beta chains from
HA peptide was iodinated by incubation of HA (50 ml of 1 mM
DR1 haplotype. Proc. Natl. Acad. Sci. USA 82, 3405±3409.
solution) with 125I and 50 mM NaPO4 (20 ml), pH 7.5, in a iodogen-
BeÂ naroch, P., Yilla, M., Raposo, G., Ito, K., Miwa, K., Geuze, H.J., andcoated glass tube on ice for 10 min. 125I±HA was separated from
Ploegh, H. (1995). How MHC class II molecules reach the endocyticfree 125I by passage over a C18 Sep-pack column, and eluted with
pathway. EMBO J. 14, 37±49.acetonitrile. Aliquots of 125I±HA were dried in a speed-vac and redis-
solved in digestion buffer for incubation with cathepsin S±treated Bennett, K., Levine, T., Ellis, J.S., Peanasky, R.J., Samloff, I.M., Kay,
J., and Chain, B.M. (1992). Antigen processing for presentation byand nontreated immunopecipitates. Following incubation with the
peptide, samples were diluted to 0.8 ml with lysis buffer (pH 7.4), class II major histocompatibility complex requires cleavage by ca-
thepsin E. Eur. J. Immunol. 22, 1519±1524.cleared of LN-2 antibody with protein A±agarose, and immunopre-
cipitated with TuÈ 36. Samples were washed thoroughly prior to addi- Bijlmakers, M.-J.E., BeÂnaroch, P., and Ploegh, H.L. (1994). Mapping
tion of SDS±PAGE sample buffer to remove unbound peptide. functional regions in the lumenal domain of the class II±associated
invariant chain. J. Exp. Med. 180, 623±629.
In Vitro Translation of a, b, and Ii Blum, J.S., and Cresswell, P. (1988). Role for intracellular proteases
cDNAs of HLA-DR1 a (Larhammar et al., 1982) and b chains (Bell in the processing and transport of class II HLA antigens. Proc. Natl.
et al., 1985), and the cDNA encoding the human p33 Ii (Claesson et Acad. Sci. USA 85, 3975±3979.
al., 1983), were all cloned in pSP72 (Promega, Madison, Wisconsin)
BroÈ mme, D., and McGrath, M.E. (1996). High levels of expression
as described previously (Bijlmakers et al., 1994). The cDNAs were
of human cathepsin S and its crystallization. Protein Sci., in press.
transcribed in vitro, either together or separately, using T7 RNA
BroÈ mme, D., Steinert, A., Friebe, S., Fittkau, S., Wiederanders, B.,polymerase. RNA was stored in 70% ethanol at 2808C. The optimal
and Kirschke, H. (1989). The specificity of bovine spleen cathepsinamount of RNA utilized was determined empirically for each sepa-
S. Scand. Biochem. J. 264, 475±481.rate batch of RNA. The resulting RNAs were translated in vitro in
rabbit reticulocyte lysate (Flexi, Promega), supplemented with ca- BroÈ mme, D., Bonneau, P.R., Lachance, P., Wiederanders, B.,
nine microsomes prepared in the laboratory of Dr. H. Ploegh. Trans- Kirschke, H., Peters, C., Thomas, D.Y., Storer, A.C., and Vernet, T.
lations were performed for 90 min at 308C, as previously described (1993). Functional expression of human cathepsin S in Saccharo-
(Bijlmakers et al., 1994). Upon completion of translation the micro- myces cerevisiae. J. Biol. Chem. 268, 4832±4838.
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